NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures... Show more
A.I.dvisor indicates that over the last year, NPCE has been loosely correlated with ESTA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NPCE jumps, then ESTA could also see price increases.
| Ticker / NAME | Correlation To NPCE | 1D Price Change % | ||
|---|---|---|---|---|
| NPCE | 100% | -5.46% | ||
| ESTA - NPCE | 46% Loosely correlated | -8.70% | ||
| CBLL - NPCE | 40% Loosely correlated | -4.46% | ||
| STVN - NPCE | 37% Loosely correlated | -4.25% | ||
| UFPT - NPCE | 34% Loosely correlated | -3.00% | ||
| OFIX - NPCE | 34% Loosely correlated | -11.43% | ||
More | ||||
| Ticker / NAME | Correlation To NPCE | 1D Price Change % |
|---|---|---|
| NPCE | 100% | -5.46% |
| Medical/Nursing Services industry (139 stocks) | -6% Poorly correlated | -4.25% |
| Health Services industry (240 stocks) | -6% Poorly correlated | -3.13% |
Industry MedicalNursingServices
The RSI Indicator for NPCE moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 24 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on NPCE as a result. In 79 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for NPCE just turned positive on October 20, 2026. Looking at past instances where NPCE's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +0.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where NPCE advanced for three days, in 236 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 55 cases where NPCE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NPCE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NPCE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NPCE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NPCE's P/B Ratio (35.529) is slightly higher than the industry average of (4.201). P/E Ratio (-21.579) is within average values for comparable stocks, (1.335). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (4.427) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. NPCE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NPCE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.